[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinylmethanone | 124443-70-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: [1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinylmethanone
• 英文别名: 4-[1-(4-fluoro-benzyl)-1H-benzoimidazole-2-carbonyl]-piperidine；4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidine；1-[[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl][1-(4-piperidinyl)]methanone；4-[1-(4-fluoro-benzyl)-1 H-benzoimidazole-2-carbonyl]-piperidine；[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]-piperidin-4-ylmethanone
• CAS: 124443-70-5
• 化学式: C₂₀H₂₀FN₃O
• 分子量: 337.397
• InChiKey: PFRRRXFREJFWAK-UHFFFAOYSA-N

物化性质

• 沸点：
  542.0±60.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinylmethanone 、 2-[3-(3,4-dichloro-phenyl)-1-(3,4,5-trimethoxy-benzoyl)-pyrrolidin-3-yl]-ethyl-methanesulfonate 在 氨 、 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 生成 1-(3,4,5-Trimethoxy-benzoyl)-3-[2-[4-[1-(4-fluoro-benzyl)-1H-benzoimidazole-2-carbonyl]-piperidin-1-yl]-ethyl]-3-(3,4-dichloro-phenyl)-pyrrolidine
  参考文献：
  名称：

  Substituted piperidines useful for the treatment of allergic diseases

  摘要：

  本发明涉及一种新型的取代哌啶衍生物，其化学式为其立体异构体和药学上可接受的盐，可用作组胺受体拮抗剂和速激肽受体拮抗剂。这类拮抗剂在治疗过敏性疾病中很有用，包括：季节性鼻炎、过敏性鼻炎和鼻窦炎。

  公开号：

  US06329392B1
• 作为产物：
  描述：

  4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]carbonyl]-1-piperidinecarboxylic acid,1,1-dimethylethyl ester 在 四氢呋喃 、 碳酸氢钠 作用下， 生成 [1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinylmethanone
  参考文献：
  名称：

  Synthesis and sar of 4-(1H-benzimidazole-2-carbonyl)piperidines with dual histamine H1/tachykinin NK1 receptor antagonist activity

  摘要：

  A series of 4-(1H-benzimidazole-2-carbonyl)piperidines with dual histamine H-1/tachykinin NK1 receptor antagonist activity has been prepared, Factors affecting receptor binding affinities and oral activity in this series are described. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10097-x

文献信息

• [EN] BENZIMIDAZOLES FOR THE TREATMENT OF CANCER<br/>[FR] BENZIMIDAZOLES POUR LE TRAITEMENT D'UN CANCER
  申请人：MAX PLANCK GESELLSCHAFT

  公开号：WO2014027053A1

  公开（公告）日：2014-02-20

  The present invention relates to novel substituted benzimidazoles and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted benzimidazoles together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted benzimidazoles binding to the prenyl binding pocket of PDEδ have been identified as useful for the prophylaxis and treatment of cancer by the inhibition of the binding of PDEδ to K-Ras and of oncogenic Ras signalling in cells by altering its localization leading to cell death or inhibition of proliferation.

  本发明涉及新型取代苯并咪唑和立体异构体形式，以及这些化合物的前药、溶剂化合物、水合物和/或药学上可接受的盐，以及含有至少一种这些取代苯并咪唑的药物组合物，与药学上可接受的载体、赋形剂和/或稀释剂一起。已经确定这些新型取代苯并咪唑结合到PDEδ的藤黄素结合口袋，对于通过抑制PDEδ与K-Ras的结合以及通过改变其定位导致细胞死亡或抑制增殖而对癌症的预防和治疗是有用的。
• Substituted piperidines useful for the treatment of allergic diseases
  申请人：Aventis Pharmaceuticals, Inc.

  公开号：US06329392B1

  公开（公告）日：2001-12-11

  The present invention relates to novel substituted piperidine derivatives of the formula stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic diseases including: seasonal rhinitis, allergic rhinitis, and sinusitis.

  本发明涉及一种新型的取代哌啶衍生物，其化学式为其立体异构体和药学上可接受的盐，可用作组胺受体拮抗剂和速激肽受体拮抗剂。这类拮抗剂在治疗过敏性疾病中很有用，包括：季节性鼻炎、过敏性鼻炎和鼻窦炎。
• Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides
  申请人：Hoescht Marion Roussel, Inc.

  公开号：US05998439A1

  公开（公告）日：1999-12-07

  The present invention relates to novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide derivatives of the formula ##STR1## stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

  本发明涉及新的取代N-甲基-N-(4-(哌啶-1-基)-2-(芳基)丁基)苯甲酰胺衍生物，其化学式为##STR1##以及其立体异构体和药学上可接受的盐，这些衍生物可用作组胺受体拮抗剂和快速激肽受体拮抗剂。这些拮抗剂在过敏性鼻炎的治疗中有用，包括季节性鼻炎和鼻窦炎；炎症性肠病，包括克罗恩病和溃疡性结肠炎；哮喘；支气管炎；以及呕吐。
• Antihistaminic piperidinyl benzimidazoles
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US04908372A1

  公开（公告）日：1990-03-13

  The present invention is directed to a new class of piperidinyl benzimidazole antihistamines which can be described by the following formula: ##STR1## wherein Y is represented by CO or CHOH; m is an integer from 1 to 2; R is represented by C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen, hydroxy and hydrogen, X is represented by hydrogen, COOR.sub.2 in which R.sub.2 is represented by a C.sub.1-4 alkyl, or X is an alkylene phenyl radical of the formula: ##STR2## wherein T is represented by CHOH, CO, O, or a direct bond; R.sub.1 is represented by C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen, hydroxy, 2,2-dimethyl ethanoic acid and hydrogen; n is an integer from 1 to 5; or a pharmaceutically acceptable acid addition salt thereof.

  本发明涉及一种新型的哌啶基苯并咪唑类抗组胺药物，其可以由以下公式描述：##STR1## 其中，Y代表CO或CHOH；m为1至2的整数；R代表C.sub.1-4烷基，C.sub.1-4烷氧基，卤素，羟基和氢原子；X代表氢原子，COOR.sub.2，其中R.sub.2代表C.sub.1-4烷基，或X为以下式子的烷基苯基基团：##STR2## 其中，T代表CHOH，CO，O或直接键；R.sub.1代表C.sub.1-4烷基，C.sub.1-4烷氧基，卤素，羟基，2,2-二甲基乙酸和氢原子；n为1至5的整数；或其药学上可接受的酸加盐。
• Process for preparing piperidinyl benzimidazoles
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05182399A1

  公开（公告）日：1993-01-26

  The present invention is directed to a new class of piperidinyl benzimidazole antihistamines which can be described by the following formula: ##STR1## wherein Y is represented by CO or CHOH; m is an integer from 1 to 2; R is represented by C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen, hydroxy and hydrogen; X is represented by hydrogen, COOR.sub.2, in which R.sub.2 is represented by a C.sub.1-4 alkyl, or an alkylene phenyl radical of the formula: ##STR2## wherein T is represented by CHOH, CO, O, or a direct bond; R.sub.1 is represented by C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen, hydroxy, 2,2-dimethyl ethanoic acid and hydrogen; n is an integer from 1 to 5; and the pharmaceutically acceptable acid addition salts thereof.

  本发明涉及一种新型的哌啶基苯并咪唑类抗组胺药物，其可由以下公式描述：##STR1## 其中，Y由CO或CHOH表示；m为1至2的整数；R由C.sub.1-4烷基，C.sub.1-4烷氧基，卤素，羟基和氢表示；X由氢，COOR.sub.2（其中，R.sub.2表示C.sub.1-4烷基，或具有以下公式的烷基苯基基团：##STR2## 其中，T由CHOH，CO，O或直接键表示；R.sub.1由C.sub.1-4烷基，C.sub.1-4烷氧基，卤素，羟基，2,2-二甲基乙酸和氢表示；n为1至5的整数；以及其药学上可接受的酸盐。